SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form F-3 - Registration statement by foreign private issuers:
SEC Accession No. 0001640334-21-003105
Filing Date
2021-12-09
Accepted
2021-12-09 16:55:30
Documents
9

Document Format Files

Seq Description Document Type Size
1 FORM F-3 nymox_f3.htm F-3 412945
2 EX-5.1 nymox_ex51.htm EX-5.1 27522
3 EX-10.1 nymox_ex101.htm EX-10.1 333321
4 EX-10.3 nymox_ex103.htm EX-10.3 12003
5 EX-23.1 nymox_ex231.htm EX-23.1 2020
6 EX-23.2 nymox_ex232.htm EX-23.2 2033
7 nymox_f3img1.jpg GRAPHIC 2967
8 nymox_f3img2.jpg GRAPHIC 2925
9 nymox_f3img3.jpg GRAPHIC 2925
  Complete submission text file 0001640334-21-003105.txt   803366
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: F-3 | Act: 33 | File No.: 333-261571 | Film No.: 211482596
SIC: 2835 In Vitro & In Vivo Diagnostic Substances